辛伐他汀对冠心病患者纤溶参数的影响

目的了解冠心病患者纤溶参数的变化,并观察辛伐他汀对冠心病患者纤溶参数的影响。方法测定87例正常对照者和108例冠心病患者血浆组织型纤溶酶原激活物(t-PA)活性和纤溶酶原激活物抑制物-(1PAI-1)活性,随后108例冠心病患者被随机分成常规治疗组和常规治疗+辛伐他汀40mg每日一次(辛伐他汀组)。治疗14d后复测t-PA活性和PAI-1活性。结果与正常对照组相比较,冠心病患者纤溶参数异常,t-PA活性下降,PAI-1活性上升(P<0.01)。常规治疗组治疗后纤溶参数无显著变化(P>0.05)。辛伐他汀组纤溶参数明显改善,表现为t-PA活性上升,PAI-1活性下降(P<0.01)。结论冠心病患者纤溶参数明显异常,辛伐他汀能改善冠心病患者纤溶参数。

Effect of simvastatin on plasma fibrinolytic parameters in patients with coronary heart disease

Objective The study was to investigate the changes of the plasma fibrinolytic parameters in patients with coronary heart disease (CHD) and to determin whether simvastatin influence plasama fibrinolytoic parameters. Methods Plasma tissue plasminogen activator (t-PA) activity and plasminogen activator inhibitor type-1(PAI-1) activity were detected in 87 normal controls and 108 patients with CHD. 108 patients with CHD were randomized to receive simvastatin 40 mg in additon to conventional therapy or only conventional therapy for 14 days. Plasma t-PA and PAI-1 activities were detected at baseline and 14 days after treatment. Results Compared with normal controls, CHD patients had decreased t-PA activity (P<0.01= and increased PAI-1 activity (P<0.01=. Administration of simvastatin was associated with increased t-PA activity (P<0.01= and decreased PAI-1 activity (P<0.01=. No significant changes were found on conventional therapy (P>0.05). Conclusion Plasma t-PA and PAI-1 activities are abnormal in CHD patients. Simvastatin is associated with a singnificant improvement of plasma of plasma fibrinolytic parameters in patients with CHD.